Related Experiment Video
Updated: May 1, 2026
07:17
Purification of Hsp104, a Protein Disaggregase
Published on: September 30, 2011
17.0K
Reversing deleterious protein aggregation with re-engineered protein disaggregases
Meredith E Jackrel1, James Shorter1
1Department of Biochemistry and Biophysics; Perelman School of Medicine at the University of Pennsylvania; Philadelphia, PA USA.
Cell Cycle (Georgetown, Tex.)
|April 4, 2014
Summary
Researchers re-engineered yeast Hsp104 to create potent variants that reverse toxic protein misfolding in neurodegenerative diseases like Parkinson disease (PD) and Alzheimer disease (AD). These variants clear protein aggregates and suppress neurodegeneration.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Aberrant protein folding causes neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), Huntington disease (HD), and Alzheimer disease (AD).
- These diseases are characterized by mislocalized protein deposits, and current treatments only manage symptoms, failing to eliminate toxic protein conformers.
- Restoring proteostasis by upregulating chaperones presents a promising therapeutic strategy for protein-misfolding disorders.
Purpose of the Study:
- To discuss the re-engineering of yeast Hsp104, a powerful disaggregase, to reverse protein misfolding implicated in human neurodegenerative diseases.
- To present the development and application of potentiated Hsp104 variants for therapeutic intervention in protein-misfolding disorders.
- To explore future directions for optimizing Hsp104 variants for clinical use.
Main Methods:
- Re-engineering the yeast prion disaggregase Hsp104 to enhance its protein disaggregase activity.
- Testing potentiated Hsp104 variants for their ability to suppress toxicity associated with TDP-43, FUS, and α-synuclein in yeast models.
- Evaluating the efficacy of Hsp104 variants in clearing protein aggregates and reversing cellular mislocalization.
- Assessing the therapeutic potential of Hsp104 variants in an animal model of Parkinson disease (PD) by examining dopaminergic neurodegeneration.
Main Results:
- Potentiated Hsp104 variants effectively suppressed TDP-43, FUS, and α-synuclein toxicity in yeast.
- These variants demonstrated the ability to eliminate protein aggregates and reverse their cellular mislocalization.
- Hsp104 variants successfully suppressed dopaminergic neurodegeneration in a relevant animal model of PD.
- The engineered Hsp104 variants show significant potential for treating protein-misfolding disorders.
Conclusions:
- Re-engineered Hsp104 variants represent a novel therapeutic strategy for reversing protein misfolding in neurodegenerative diseases.
- These variants offer a promising approach to eliminate toxic protein conformers and restore proteostasis.
- Further development of potentiated Hsp104 variants could lead to effective treatments for ALS, PD, HD, and AD.
Related Concept Videos
02:18The Proteasome
7.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.8K
01:13The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
01:32Export of Misfolded Proteins out of the ER
4.3K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
4.3K
01:37The Unfolded Protein Response
5.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.6K
02:11Proteins: From Genes to Degradation
11.9K
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick. Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA...
Transcription is the synthesis of RNA...
11.9K
02:58Regulated Protein Degradation
6.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K